Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Up 8.2% in December

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,840,000 shares, an increase of 8.2% from the December 15th total of 3,550,000 shares. Based on an average daily volume of 463,300 shares, the days-to-cover ratio is currently 8.3 days.

Aldeyra Therapeutics Stock Performance

NASDAQ ALDX traded up $0.06 during trading on Monday, reaching $4.84. 274,810 shares of the stock traded hands, compared to its average volume of 370,307. Aldeyra Therapeutics has a fifty-two week low of $2.71 and a fifty-two week high of $6.55. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18. The stock's 50-day moving average price is $4.94 and its 200 day moving average price is $4.98.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, meeting the consensus estimate of ($0.25). Equities research analysts predict that Aldeyra Therapeutics will post -0.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its position in shares of Aldeyra Therapeutics by 21.7% in the second quarter. Bank of New York Mellon Corp now owns 195,722 shares of the biotechnology company's stock worth $648,000 after purchasing an additional 34,885 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Aldeyra Therapeutics by 20.1% in the second quarter. Rhumbline Advisers now owns 76,981 shares of the biotechnology company's stock worth $255,000 after purchasing an additional 12,907 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Aldeyra Therapeutics by 216.7% in the second quarter. American Century Companies Inc. now owns 53,388 shares of the biotechnology company's stock worth $177,000 after purchasing an additional 36,528 shares in the last quarter. Federated Hermes Inc. bought a new stake in shares of Aldeyra Therapeutics in the second quarter worth $1,758,000. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Aldeyra Therapeutics by 14.4% in the second quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company's stock worth $72,000 after purchasing an additional 2,729 shares in the last quarter. Institutional investors and hedge funds own 59.71% of the company's stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.